Loading
Rocbrutinib is an experimental small-molecule drug from Guangzhou Lupeng Pharmaceutical in phase 3 trials for mantle cell lymphoma, chronic lymphocytic leukaemia and diffuse large B-cell lymphoma, with its target not yet stated publicly.
Rocbrutinib (NWP-775, LP-168) is a small-molecule drug developed by Guangzhou Lupeng Pharmaceutical and Newave Pharmaceutical. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. ClinicalTrials.gov describes the intervention as: 200mg qd PO. The treatment will continue until progressive disease, unacceptable toxicity, etc. It is the investigational product in 4 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including phase 3 studies NCT07377578 (A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma) and NCT07342478 (ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL), in mantle cell lymphoma, chronic lymphocytic leukaemia and diffuse large B-cell lymphoma. The largest, NCT07377578, plans to enrol 394 participants with primary completion expected 2031-05-30. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
Ball-and-stick model from PubChem 2D record (no 3D conformer available). PubChem record
Mechanism not stated in the ClinicalTrials.gov record or on the sponsor's pipeline page.
1.Rocbrutinib slips into a pocket on its target.
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Rocbrutinib" OR ABSTRACT:"Rocbrutinib" OR TITLE:"NWP-775" OR ABSTRACT:"NWP-775" OR TITLE:"LP-168" OR ABSTRACT:"LP-168") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Rocbrutinib, not a curated reading list.
Shares Lupeng Pharmaceuticals, Chronic lymphocytic leukaemia and the tag pipeline.
Shares Mantle cell lymphoma, Chronic lymphocytic leukaemia, Diffuse large B-cell lymphoma and the tag pipeline.
Shares Mantle cell lymphoma, Chronic lymphocytic leukaemia, Diffuse large B-cell lymphoma and the tag pipeline.
Shares Mantle cell lymphoma, Chronic lymphocytic leukaemia, Diffuse large B-cell lymphoma and the tag pipeline.
Shares Chronic lymphocytic leukaemia, Diffuse large B-cell lymphoma and the tag pipeline.
Shares Mantle cell lymphoma, Diffuse large B-cell lymphoma and the tag pipeline.
Shares Mantle cell lymphoma, Chronic lymphocytic leukaemia and the tag pipeline.
Shares Chronic lymphocytic leukaemia, Diffuse large B-cell lymphoma and the tag pipeline.